Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 42

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 42
---
 from product sales may be lower than if we had commercialized our product candidates
ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product
candidates.

<div align='center'>18</div>

There can be no assurance
that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party
collaborators to commercialize any product in the United States or overseas.

We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more rapidly than we do, if their platform technologies or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected.

The development and commercialization
of cell and gene therapies Is highly competitive. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical
companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology and/or therapeutics being
developed at universities and other research institutions. Our competitors are often larger and better funded than we are. Our competitors
have developed, are developing or will develop product candidates and processes competitive with ours. Competitive therapeutic treatments
include those that have already been approved and accepted by the medical community and any new treatments that are currently in development
or that enter the market. We believe that a significant number of product candidates are currently under development, and may become
commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. There is intense
and rapidly evolving competition in the biotechnology and biopharmaceutical fields. We believe that while our T-cell based platform,
its associated intellectual property portfolio, the characteristics of our current and potential future product candidates and our scientific
and technical know-how together give us a competitive advantage in this space, competition from many sources remains.

Many of our competitors
have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we
successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety
and effectiveness of our product candidates, the ease with which our product candidates can be administered, the timing and scope of
regulatory approvals for these product candidates, the availability and cost of manufacturing, marketing and sales capabilities, price,
reimbursement